Drugs

, Volume 71, Issue 17, pp 2257–2275 | Cite as

Adjuvant Therapy for Early Colon Cancer

Current Status
  • Alexander Stein
  • Sonja Hiemer
  • Hans-Joachim Schmoll
Therapy in Practice

Abstract

Adjuvant chemotherapy after resection of the primary tumour reduces the risk of death by an absolute 5% in UICC (Union Internationale Contre le Cancer) stage II colon cancer and about 15–20% in stage III. Adjuvant treatment has to be evaluated separately for each stage due to the different clinical situations: in stage II about 80% of patients are cured by surgery alone, whereas only about half of patients with stage III are cured by surgery. Decisions on adjuvant treatment need to be discussed with the patient on an individual basis, and take into account patient characteristics (performance status, age, co-morbidity and patient preference) as well as cancer features (pathological stage, grading and overall risk of relapse).

Recently, capecitabine in combination with oxaliplatin has been approved for treatment of stage III colon cancer, providing the benefits of an oral fluoropyrimidine. Predictive markers for guidance of treatment have gained importance, particularly in stage II disease. Microsatellite instability, a well known prognostic factor, might be predictive for a lack of activity of fluorouracil treatment in some stage II patients. Furthermore, patients aged ≥70 years do not seem to obtain the same benefit from combination therapy compared with those aged <70 years. The impact of these current developments on daily clinical practice is discussed in this review.

Notes

Acknowledgements

The manuscript was prepared without any funding or contribution of persons not mentioned in the authors’ section. AS and SH have no conflicts of interest to declare. HJS has received honoraria for consultant or advisory work from Roche, and research grant support from Roche and Merck Serono.

References

  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765–81PubMedCrossRefGoogle Scholar
  2. 2.
    Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127(12): 2893–917PubMedCrossRefGoogle Scholar
  3. 3.
    La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol 2010; 21: 1323–60PubMedCrossRefGoogle Scholar
  4. 4.
    Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010; 28: 264–71PubMedCrossRefGoogle Scholar
  5. 5.
    Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664–70PubMedCrossRefGoogle Scholar
  6. 6.
    de Gramont A, Hubbard J, Shi Q, et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 2010; 28: 460–5PubMedCrossRefGoogle Scholar
  7. 7.
    Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–8PubMedCrossRefGoogle Scholar
  8. 8.
    Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988; 80: 30–6PubMedCrossRefGoogle Scholar
  9. 9.
    Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes’ A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02. J Clin Oncol 1990; 8: 1466–75PubMedGoogle Scholar
  10. 10.
    Smith RE, Colangelo L, Wieand HS, et al. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004; 96: 1128–32PubMedCrossRefGoogle Scholar
  11. 11.
    Porschen R, Bermann A, Loffler T, et al. Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001; 19: 1787–94PubMedGoogle Scholar
  12. 12.
    Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Inter-group 0089. J Clin Oncol 2005; 23: 8671–8PubMedCrossRefGoogle Scholar
  13. 13.
    Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17: 3553–9PubMedGoogle Scholar
  14. 14.
    O’Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295–300PubMedGoogle Scholar
  15. 15.
    QUASAR Collaborative Group. Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588–96CrossRefGoogle Scholar
  16. 16.
    Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896–903PubMedCrossRefGoogle Scholar
  17. 17.
    Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433–41PubMedCrossRefGoogle Scholar
  18. 18.
    Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 2008; 51: 503–7PubMedCrossRefGoogle Scholar
  19. 19.
    O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420–5PubMedCrossRefGoogle Scholar
  20. 20.
    Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912–9PubMedCrossRefGoogle Scholar
  21. 21.
    Prandi M, Lionetto R, Bini A, et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235: 458–63PubMedCrossRefGoogle Scholar
  22. 22.
    Watanabe T, Wu TT, Catalano PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196–206PubMedCrossRefGoogle Scholar
  23. 23.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor micro-satellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247–57PubMedCrossRefGoogle Scholar
  24. 24.
    Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466–74PubMedCrossRefGoogle Scholar
  25. 25.
    Roth A, Tejpar S. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [abstract]. J Clin Oncol 2009; 27: 4002CrossRefGoogle Scholar
  26. 26.
    Goldberg RM, Sargent DJ. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0 147 [abstract]. J Clin Oncol 2010; 28: 3508Google Scholar
  27. 27.
    Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer [published erratum appears in J Clin Oncol 2011; 29 (21): 2949]. J Clin Oncol 2011; 29(10): 1261–70PubMedCrossRefGoogle Scholar
  28. 28.
    Kerr D, Gray R. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract]. J Clin Oncol 2009; 27: 4000Google Scholar
  29. 29.
    Rosenberg R, Maak M. Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients [abstract]. J Clin Oncol 2011; 29: 358CrossRefGoogle Scholar
  30. 30.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609–18PubMedCrossRefGoogle Scholar
  31. 31.
    Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69–77PubMedCrossRefGoogle Scholar
  32. 32.
    Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248–57PubMedGoogle Scholar
  33. 33.
    Balmana J, Castells A, Cervantes A. Familial colorectal cancer risk: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 Suppl. 5: v78–81PubMedCrossRefGoogle Scholar
  34. 34.
    Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45: 365–73PubMedCrossRefGoogle Scholar
  35. 35.
    Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219–26PubMedCrossRefGoogle Scholar
  36. 36.
    Lanza G, Gafa R, Santini A, et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359–67PubMedCrossRefGoogle Scholar
  37. 37.
    Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011; 103(11): 863–75PubMedCrossRefGoogle Scholar
  38. 38.
    Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126: 394–401PubMedCrossRefGoogle Scholar
  39. 39.
    Tejpar S, Bosman F. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993- SAKK 60/00 trial) [abstract]. J Clin Oncol 2009; 27: 4001Google Scholar
  40. 40.
    Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767–72PubMedCrossRefGoogle Scholar
  41. 41.
    Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes’ C colon carcinoma. Oncology 2000; 58: 52–9PubMedCrossRefGoogle Scholar
  42. 42.
    Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020–9PubMedCrossRefGoogle Scholar
  43. 43.
    Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003; 63: 5738–44PubMedGoogle Scholar
  44. 44.
    Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009; 27: 1814–21PubMedCrossRefGoogle Scholar
  45. 45.
    Zaanan A, Flejou J. Microsatellite instability status as a predictive marker of clinical outcome from FOLFOX adjuvant chemotherapy in stage III colon cancer [abstract]. J Clin Oncol 2011; 29 (Suppl.): 493Google Scholar
  46. 46.
    Schmiegel W, Pox C, Arnold D, et al. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int 2009; 106: 843–8PubMedGoogle Scholar
  47. 47.
    Labianca R, Nordlinger B, Beretta GD, et al. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21 Suppl. 5: v70–7PubMedCrossRefGoogle Scholar
  48. 48.
    Barrier A, Boelle PY, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24: 4685–91PubMedCrossRefGoogle Scholar
  49. 49.
    Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23: 3526–35PubMedCrossRefGoogle Scholar
  50. 50.
    Lin YH, Friederichs J, Black MA, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007; 13: 498–507PubMedCrossRefGoogle Scholar
  51. 51.
    Salazar R, Roepman P, Capella G, et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2011; 29: 17–24PubMedCrossRefGoogle Scholar
  52. 52.
    Li MC, Ross ST. Chemoprophylaxis for patients with colorectal cancer: prospective study with five-year follow-up. JAMA 1976; 235(26): 2825–8PubMedCrossRefGoogle Scholar
  53. 53.
    Moertel CG, Fleming TR, Macdonald JS, et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995; 13: 2936–43PubMedGoogle Scholar
  54. 54.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17: 1356–63Google Scholar
  55. 55.
    Mamounas E, Wieand S, Wolmark N, et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349–55PubMedGoogle Scholar
  56. 56.
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22: 1797–806PubMedCrossRefGoogle Scholar
  57. 57.
    Francini G, Petrioli R, Lorenzini L, et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899–906PubMedGoogle Scholar
  58. 58.
    Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447–56Google Scholar
  59. 59.
    Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939–44CrossRefGoogle Scholar
  60. 60.
    Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872–7PubMedCrossRefGoogle Scholar
  61. 61.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343–51PubMedCrossRefGoogle Scholar
  62. 62.
    Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109–16PubMedCrossRefGoogle Scholar
  63. 63.
    Teixeira L, Hickish T. Efficacy of FOLFOX4 as adjuvant therapy in stage II colon cancer (CC): a new analysis of the MOSAIC trial according to risk factors [abstract]. J Clin Oncol 2010; 28: 3524Google Scholar
  64. 64.
    Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198–204PubMedCrossRefGoogle Scholar
  65. 65.
    Wolmark N, Wieand S. A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: Survival results of NSABP Protocol C-07 [abstract]. J Clin Oncol 2008; 26: LBA4005Google Scholar
  66. 66.
    Yothers G, Allegra C. The efficacy of oxaliplatin (Ox) when added to 5-fluorouracil/leucovorin (FU/L) in stage II colon cancer [abstract]. J Clin Oncol 2011; 29 Suppl.: 3507CrossRefGoogle Scholar
  67. 67.
    Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117–25PubMedCrossRefGoogle Scholar
  68. 68.
    Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Co-chrane Database Syst Rev 2008; 16(3): CD005390Google Scholar
  69. 69.
    Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704PubMedCrossRefGoogle Scholar
  70. 70.
    Lembersky BC, Wieand HS, Petrelli NJ, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059–64PubMedCrossRefGoogle Scholar
  71. 71.
    Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011; 29: 1465–71PubMedCrossRefGoogle Scholar
  72. 72.
    Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011; 18: 18–25PubMedCrossRefGoogle Scholar
  73. 73.
    Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25: 102–9PubMedCrossRefGoogle Scholar
  74. 74.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009; 27: 3385–90PubMedCrossRefGoogle Scholar
  75. 75.
    Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456–61PubMedCrossRefGoogle Scholar
  76. 76.
    Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2+irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009; 20: 674–80PubMedCrossRefGoogle Scholar
  77. 77.
    Wolmark N, Yothers G. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08 [abstract]. J Clin Oncol 2009; 27: LBA4Google Scholar
  78. 78.
    Cassidy J, Cox JV. Effective management of patients receiving XELOX: evaluation of impact of dose modifications on outcome in patients from the NO16966, NO16967, and NO16968 trials [abstract]. J Clin Oncol 2011; 29: 497CrossRefGoogle Scholar
  79. 79.
    Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549–57PubMedCrossRefGoogle Scholar
  80. 80.
    Glimelius B, Dahl O, Cedermark B, et al. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44: 904–12PubMedGoogle Scholar
  81. 81.
    Berglund A, Cedermark B, Glimelius B. Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III? Ann Oncol 2008; 19: 400–2PubMedCrossRefGoogle Scholar
  82. 82.
    Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006; 107: 2581–8PubMedCrossRefGoogle Scholar
  83. 83.
    Biagi JJ, Raphael M. The impact of time to adjuvant chemotherapy (AC) on survival in colorectal cancer (CRC): a systematic review and meta-analysis [abstract]. J Clin Oncol 2011; 29: 364Google Scholar
  84. 84.
    Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85: 1437–43PubMedCrossRefGoogle Scholar
  85. 85.
    Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol 2007; 25: 3732–8PubMedCrossRefGoogle Scholar
  86. 86.
    Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091–7PubMedCrossRefGoogle Scholar
  87. 87.
    Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085–91PubMedCrossRefGoogle Scholar
  88. 88.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11–6PubMedCrossRefGoogle Scholar
  89. 89.
    De Gramont A, Van Cutsem E. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer [abstract]. J Clin Oncol 2011; 29: 362CrossRefGoogle Scholar
  90. 90.
    Alberts SR, Sargent D. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0 147. J Clin Oncol 2010; 28: CRA3507CrossRefGoogle Scholar
  91. 91.
    Huang J, Sargent DJ. Adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup phase III trial N0147 [abstract]. J Clin Oncol 2011; 29: 363CrossRefGoogle Scholar
  92. 92.
    Jackson McCleary NA, Meyerhardt J. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database [abstract]. J Clin Oncol 2009; 27: 4010Google Scholar
  93. 93.
    Tournigand C, Andre T. FOLFOX4 as adjuvant therapy in elderly patients (pts) with colon cancer (CC): Subgroup analysis of the MOSAIC trial [abstract]. J Clin Oncol 2010; 28: 3522Google Scholar
  94. 94.
    Yothers G, O’Connell MJ. 5-FU and leucovorin (Lv) with or without oxaliplatin (Ox) for adjuvant treatment of stage II and III colon cancer: Long-term follow-up of NSABP C-07 with survival analysis [abstract]. Gastrointest Cancer Symp 2010; abstract 401Google Scholar
  95. 95.
    Haller D, Cassidy J. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival (DFS) [abstract]. J Clin Oncol 2010; 28: 3521CrossRefGoogle Scholar
  96. 96.
    Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408–17PubMedCrossRefGoogle Scholar
  97. 97.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42PubMedCrossRefGoogle Scholar
  98. 98.
    Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539–44PubMedCrossRefGoogle Scholar
  99. 99.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45PubMedCrossRefGoogle Scholar
  100. 100.
    Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706–12PubMedCrossRefGoogle Scholar
  101. 101.
    Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040–8PubMedCrossRefGoogle Scholar
  102. 102.
    Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–65PubMedCrossRefGoogle Scholar
  103. 103.
    Tveit K, Guren T. Randomized Phase III study of 5-fluorouracil/folinate/oxaliplatin given continously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314). Ann Oncol 2010; 21: LBA 20Google Scholar
  104. 104.
    Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377(9783): 2103–14PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Alexander Stein
    • 1
  • Sonja Hiemer
    • 2
  • Hans-Joachim Schmoll
    • 2
  1. 1.University Cancer Center Hamburg, University Medical Center Hamburg-EppendorfHamburgGermany
  2. 2.Department for Oncology/HaematologyMartin Luther University HalleWittenbergGermany

Personalised recommendations